ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Back to Protocols
Beginner
12 weeks

Shred Protocol

Targeted fat loss and body recomposition while preserving lean muscle mass

Peptide Stack

Preparation

Reconstitute all peptides with bacteriostatic water. CJC-1295 and Ipamorelin can be mixed together. Fragment 176-191 should be kept separate. Store at 2-8°C and use within 2-4 weeks.

Administration

Morning (fasted): Fragment 176-191, then CJC/Ipa 15 minutes later. Pre-workout: Fragment 176-191. Before bed: CJC/Ipa. Always inject on empty stomach for Fragment 176-191. Rotate injection sites.

Monitoring

Track body weight, body fat percentage, waist circumference, and progress photos weekly. Monitor energy levels and workout performance. Most users see measurable fat loss by week 3-4.

Expected Timeline

Week 1-2: Improved metabolism and energy. Week 3-6: Noticeable fat loss, especially abdominal area. Week 7-12: Continued fat reduction and muscle definition. Best results with caloric deficit and regular exercise.

Research Basis

Fragment 176-191 is a modified fragment of human growth hormone that specifically targets fat metabolism without affecting blood sugar. Combined with GH optimization (CJC/Ipa), this protocol provides both direct lipolytic effects and improved overall metabolism.

Safety Considerations

  • Do not use if you have active cancer
  • Avoid during pregnancy or breastfeeding
  • Monitor blood glucose levels
  • Maintain adequate protein intake to preserve muscle
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Protocol Overview

A targeted fat loss protocol combining GH optimization with the lipolytic Fragment 176-191. The GH base improves overall metabolism while Frag 176-191 directly stimulates fat oxidation without affecting blood sugar.

Duration: 12 weeks Peptides: 3 Experience Level: Beginner

Peptide Stack

CJC-1295-NO-DAC

  • Dose: 100 mcg
  • Frequency: twice daily
  • Timing: morning and before bed

View CJC-1295-NO-DAC Profile

IPAMORELIN

  • Dose: 100-200 mcg
  • Frequency: twice daily
  • Timing: with CJC-1295 doses

View IPAMORELIN Profile

FRAGMENT-176-191

  • Dose: 250-500 mcg
  • Frequency: twice daily
  • Timing: morning (fasted) and pre-workout

View FRAGMENT-176-191 Profile

Preparation

Reconstitute all peptides with bacteriostatic water. CJC-1295 and Ipamorelin can be mixed together. Fragment 176-191 should be kept separate. Store at 2-8°C and use within 2-4 weeks.

Administration

Morning (fasted): Fragment 176-191, then CJC/Ipa 15 minutes later. Pre-workout: Fragment 176-191. Before bed: CJC/Ipa. Always inject on empty stomach for Fragment 176-191. Rotate injection sites.

Monitoring

Track body weight, body fat percentage, waist circumference, and progress photos weekly. Monitor energy levels and workout performance. Most users see measurable fat loss by week 3-4.

Expected Timeline

Week 1-2: Improved metabolism and energy. Week 3-6: Noticeable fat loss, especially abdominal area. Week 7-12: Continued fat reduction and muscle definition. Best results with caloric deficit and regular exercise.

Research Basis

Fragment 176-191 is a modified fragment of human growth hormone that specifically targets fat metabolism without affecting blood sugar. Combined with GH optimization (CJC/Ipa), this protocol provides both direct lipolytic effects and improved overall metabolism.

Safety Considerations

  • Do not use if you have active cancer
  • Avoid during pregnancy or breastfeeding
  • Monitor blood glucose levels
  • Maintain adequate protein intake to preserve muscle
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.

Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.